Alterations in the expression of selected MHC antigens in premalignant lesions and squamous carcinomas of the uterine cervix

Acta Obstetricia et Gynecologica Scandinavica

Volumn 82, Issue 12, 2003, Pages 1146-1152

  Chil, Arkadiusz ^a,e   Sikorski, Marek ^b   Bobek, Małgorzata ^c   Jakiel, Grzegorz ^d   Marcinkiewicz, Janusz ^c  

^a Center of Oncology of Kielce   (Poland)

^b Genix Medical Centre   (Poland)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^d MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^e NONE   (Poland)

Author keywords

Cervix; HLA antigens; Human papillomavirus

Indexed keywords

HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B ANTIGEN; HLA BW4 ANTIGEN; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; PRECANCER; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SQUAMOUS CELL CARCINOMA; SQUAMOUS CELL METAPLASIA; UPREGULATION; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU;

BIOPSY, NEEDLE; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; COHORT STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOHISTOCHEMISTRY; PRECANCEROUS CONDITIONS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 0344084246     PISSN: 00016349     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1600-0412.2003.00252.x     Document Type: Article

References (32)

1. Gissmann L, Muller M. Serological immune response to HPV. In: Stern PL, Stanley MA, eds. Human papillomaviruses and cervical cancer. Oxford: Oxford Medical Publications, 1994: 141.
2. Coleman N, Birley HDL, Renton AM, Hanna NF, Ryait BK, Byrne M. Immunological events in regressing genital warts. Am J Clin Pathol 1994; 102: 768-74.
3. Connor ME, Stern PL. Loss of MHC class I expression in cervical carcinomas. Int J Cancer 1990; 46: 1029-34.
4. Duggan-Keen M, Keating P, Cromme FV, Walboomers JMM, Stern PL. Alterations in major histocompatibility complex expression in cervical cancer: possible consequences for immunotherapy. In: Papillomavirus reviews: current research on papillomavirusues. Leeds: Leeds Medical Information, 1995.
5. Garrido F, Cabrera A, Concha A, Glew SS, Ruiz-Cabello F, Stern PL. Natural history of HLA expression during tumor development. Immunol Today 1993; 14: 491-9.
6. Cromme FV, Snijders PJ, van den Brule AJ, Kenemans P, Meijer CJ, Walboomers JM. MHC class I expression in HPV 16 cervical carcinomas is post-transcriptionally controlled and independent from c-myc overexpression. Oncogene 1993; 11: 2969-75.
7. Hilders CG, Munoz IM, Nooyen I, Fleuren GJ. Altered HLA expression by metastatic cervical carcinoma cells as a factor in impaired immune surveillance. Gynecol Oncol 1995; 57: 366-75.
8. Connor ME, Davidson SE, Stern PL, Arrand JR, West CML. Evaluation of multiple biological parameters in cervical carcinoma: high macrophage infiltration in HPV-associated tumors. Int J Gynecol Cancer 1993; 3: 103-9.
9. Cromme FV, Airey J, Heemels MT, Ploegh HL, Keating PJ, Stern PL et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 1994; 179: 335-40.
10. Ljungren HG, Karre K. Variations in MHC antigen expression on tumors and its significance. J Immunogenet 1986; 13: 141-51.
11. Glew SS, Connor ME, Snijders PJ, Stanbridge CM, Buckley CH, Walboomers J et al. HLA expression in pre-invasive cervical neoplasia in relation to human papillomavirus infection. Eur J Cancer 1993; 29A: 1963-70.
12. Hilders CG, Houbiers JG, Krul EJ, Fleuren GJ. The expression of histocompatibility-related leukocyte antigens in the pathway to cervical carcinoma. Am J Clin Pathol 1994; 101: 5-12.
13. Glew SS, Duggan-Keen M, Cabrear T, Stern PL. HLA class II antigen expression in human papillomavirus associated cervical cancer. Cancer Res 1992; 52: 4009-16.
14. Daar AS, Fuggle SV, Fabre JW. The detailed distribution of HLA-A,B,C antigens in normal human organs. Transplantation 1984; 38: 287-32.
15. Adams TE, Bodner JG, Bodner WF. Production and characterization of monoclonal antibodies recognising the alpha-chain subunits of human Ia alloantigens. Immunology 1992; 50: 613-24.
16. van den Berg FM, Baas IO, Polak MM, Offerhaus GJA. Detection of p53 over-expression in routinely paraffin embedded tissue of human carcinomas using a novel target unmasking fluid (TUF). Am J Pathol 1993; 142: 381-5.
17. van Driel WJ, Tjiong MY, Hilders CG, Trimbos BJ, Fleuren GJ. Association of allele specific HLA expression and histopathologic progression of cervical carcinoma. Gynecol Oncol 1996; 62: 33-41.
18. Torres LM, Cabrera T, Concha A, Oliva MR, Ruiz-Cabello F, Garrido F. HLA class I expression and HPV-16 sequences in premalignant and malignant lesions of the cervix. Tissue Antigens 1993; 41: 65-71.
19. Turner MA, Palefsky JM. Urokinase plasminogen activator expression by primary and HPV 16-transformed keratinocytes. Clin Exp Metastasis 1995; 13: 260-8.
20. Stam NJ, Spits H, Ploegh HL. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 1986; 137: 2299-306.
21. Seung S, Urban JL, Schreiber H. A tumor escape variant lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target. J Exp Med 1993; 178: 933-40.
22. Bontkes HJ, van Duin M, de Gruijl TD, Duggan Keen MF, Walboomers JM, Stukart MJ et al. HPV 16 infection and progression of cervical intra-epithelial neoplasia: analysis of HLA polymorphism and HPV 16, E6 sequence variants. Int J Cancer 1998; 78: 166-71.
23. Keating PJ, Cromme FV, Duggan-Keen M, Snijders PJ, Walboomers JM, Hunter RD et al. Frequency of down regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br J Cancer 1995; 72: 405-11.
24. Stern PL, Duggan-Keen M. MHC expression in the natural history of cervical cancer. In: Stern PL, Stanley MA, eds. Human papillomaviruses and cervical cancer. Oxford: Oxford Medical Publications, 1994: 169.
25. Bourgault Villada I, Beneton N, Bony C, Connan F, Monsonego J, Bianchi A et al. Identification in humans of HPV-16 E6 and E7 protein epitopes recognized by cytolytic T lymphocytes in association with HLA-B18 and determination of the HLA-B18-specific binding motif. Eur J Immunol 2000; 30: 2281-9.
26. Wang SS, Wheeler CM, Hildesheim A, Schiffman M, Herrero R, Bratti MC et al. Human leukocyte antigen class I and II alleles and risk of cervical neoplasia: results from a population-based study in Costa Rica. J Infect Dis 2001; 184: 1310-14.
27. Morelli AE, Sananes C, DiPaola G, Paredes A, Fainboim L. Relationship between types of human papillomavirus and Langerhans' cells in cervical condyloma and intraepithelial neoplasia. Am J Clin Pathol 1993; 99: 200-6.
28. Kerr L, Navsaria HA, Barker JNWN, Sakkas LI, Leigh IM, MacDonald DM et al. Interferon-gamma activates co-ordinate transcription of HLA-DR, DQ and DP genes in cultured keratinocytes and requires de novo protein synthesis. J Invest Dermatol 1990; 95: 653-6.
29. Cairns BA, De Serres S, Kilpatrick K, Frelinger JA, Meyer AA. Cultured keratinocyte allografts fail to induce sensitization in vivo. Surgery 1993; 114: 416-22.
30. Bal V, McIndoe A, Denton G, Hudson D, Lombardi G, Lamb J et al. Antigen presentation by keratinocytes induces tolerance in human T cells. Eur J Immunol 1990; 20: 1893-7.
31. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992; 356: 607-9.
32. Fleming TE, Mirando WS, Trefzer U, Tubesing KA, Elmets CA. In situ expression of a B7-like adhesion molecule on keratinocytes from human epidermis. J Invest Dermatol 1993; 101: 754-8.